Epirubicin Induces Cell Cycle Arrest in Multiple Myeloma Cells by Downregulating CDC20 Expression
Frontiers in Bioscience-Landmark · 2025
DOI: 10.31083/fbl46326 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2025. Verfasst von Zhen Nan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 450008 Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Cdc20 Proteins, Epirubicin, Multiple Myeloma, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Although epirubicin is used among therapeutic options for multiple myeloma (MM), its clinical use remains limited, in part because the subgroup of patients most likely to benefit has not been clearly defined. Identifying robust biomarkers capable of predicting chemosensitivity is therefore essential to aimed personalized treatment strategies and enhance therapeutic outcomes. This study sought to characterize the molecular effects of epirubicin in MM cells, elucidate its tumor-suppressive mechanisms, and determine potential indicators for patient stratification. Materials and Methods: The half-maximal inhibitory concentration (IC50) for epirubicin was quantified using the Cell Counting Kit-8 (CCK-8) viability assay. Gene expression alterations before and after epirubicin exposure were investigated via microarray profiling, followed by bioinformatic interrogation of publicly available datasets to examine the prognostic value of CDC20 expression in MM. Subsequently, functional validation was performed through in vitro assays and in vivo xenograft models to evaluate the impact of epirubicin on cell-cycle progression and tumor growth.
Results
Epirubicin exhibited an IC50 of 23.85 μM in MM.1R cells. Transcriptome analysis revealed 115 genes upregulated and 25 genes downregulated post-treatment. Among the significantly altered genes were CDC20 (log FC = –2.409), KIF20A (log FC = –1.693), FAM72A (log FC = –1.742), CCNB1 (log FC = –1.787), PIF1 (log FC = –2.201), and LMNB1 (log FC = –1.589). Higher CDC20 expression was associated with shorter overall survival (OS), event-free survival (EFS), and post-progression survival (PPS). Mechanistic studies demonstrated that epirubicin triggers G2/M arrest in MM cells by suppressing CDC20, and in vivo experiments corroborated that decreased CDC20 expression contributes to reduced tumor proliferation via cell-cycle blockade.
Conclusion
Epirubicin exerts anti-myeloma effects by downregulating CDC20 and inducing cell-cycle arrest in MM, highlighting CDC20 as a potential biomarker for identifying MM patients likely to benefit from epirubicin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 450008 Zhengzhou, Henan, China.
- Department of Hematology, Puyang Oilfield General Hospital, 457001 Puyang, Henan, China.
Zitieren
APA
Nan, Z., Wang, X., Wang, Y., Cui, Y., & Fang, B. (2025). Epirubicin Induces Cell Cycle Arrest in Multiple Myeloma Cells by Downregulating CDC20 Expression. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl46326
Vancouver
Nan Z, Wang X, Wang Y, Cui Y, Fang B. Epirubicin Induces Cell Cycle Arrest in Multiple Myeloma Cells by Downregulating CDC20 Expression. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl46326
BibTeX
@article{Nan2025,
author = {Nan, Zhen and Wang, Xueting and Wang, Yaomei and Cui, Yushan and Fang, Baijun},
title = {Epirubicin Induces Cell Cycle Arrest in Multiple Myeloma Cells by Downregulating CDC20 Expression},
journal = {Frontiers in Bioscience-Landmark},
year = {2025},
doi = {10.31083/fbl46326}
}
EUVIMED